论文部分内容阅读
据美国Imreg公司报告,用Imreg-1治疗AIDS和AIDS相关复征患者的Ⅰ、Ⅱ期研究结果令人鼓舞.Imreg-1是从人白细胞获得的免疫调节剂,实验室研究提示它能增加T细胞产生白细胞介素-2(IL-2)和其他淋巴因子.给洛杉矶市的32名患者每2或4周皮下注射Imreg-1,该项3个月的临床试验表明该药无毒性,新奥尔良市的研究结果相同.Imreg-1的优点是它不仅能增加淋巴因子的产生,还能增加许多生物应答调节
According to the American Imreg report, the Phase I and II results of patients treated with Imreg-1 for AIDS-related complex AIDS syndrome are encouraging. Imreg-1 is an immunomodulator derived from human leukocytes and laboratory studies suggest that it can increase T The cells produce interleukin-2 (IL-2) and other lymphokines. 32 patients in the city of Los Angeles were injected with Imreg-1 subcutaneously every 2 or 4 weeks. The 3-month clinical trial showed that the drug is non-toxic and new. Orleans has the same findings. The advantage of Imreg-1 is that it not only increases the production of lymphokines, but also increases many biological responses.